文献速递脑血管病

微型闭环迷走神经刺激系统在慢性卒中患者中产生持久康复效果

Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke.
PubMed 文献 · Stroke · 2025-10-07

这项随机假对照试验在19例慢性缺血性卒中患者中评估了微型闭环迷走神经刺激系统的安全性、可行性和初步有效性。结果显示不良事件性质与发生率不高于传统迷走神经刺激装置,心率血压未受影响;上肢Fugl-Meyer评分在随机对照阶段较基线提高5.3±0.7分(P<0.001),探索性延展期额外治疗提高10.9±1.3分(P<0.001)。

要点

  • 微型闭环迷走神经刺激系统安全性不劣于传统装置,心率血压不受影响。
  • 随机对照阶段上肢Fugl-Meyer评分较基线提高5.3±0.7分(P<0.001)。
  • 探索性延展期额外治疗提高上肢Fugl-Meyer评分10.9±1.3分(P<0.001)。

核心结论

  • 微型闭环迷走神经刺激系统在慢性卒中患者中安全可行,并显示出初步有效性,值得开展更大规模研究评估。

研究设计与样本

  • 随机假对照试验于2021年9月至2024年1月在达拉斯开展,纳入19例缺血性卒中至少1年且遗留上肢缺陷的参与者并植入设备。
  • 双盲阶段随机接受18次个体化渐进康复联合主动闭环迷走神经刺激或假刺激,之后无论分组均再接受18次主动刺激康复。
  • 完成主研究后部分参与者进入探索性延展期,在家接受最多100次自定节奏的闭环迷走神经刺激治疗。

主要发现

  • 不良事件性质与发生率与传统迷走神经刺激装置相似或更低。
  • 闭环迷走神经刺激未影响心率和血压。
  • 随机对照阶段主动治疗后上肢Fugl-Meyer评分较基线提高5.3±0.7分(P<0.001)。
  • 探索性延展期额外治疗使上肢Fugl-Meyer评分提高10.9±1.3分(P<0.001)。

临床怎么用

  • 该微型闭环迷走神经刺激系统可作为慢性卒中上肢康复的潜在辅助手段,需在更大规模研究中进一步验证。

局限性

  • 主研究样本量仅19例,结论需更大规模研究确认。
  • 探索性延展期结果来自部分参与者子集,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of task-oriented training and vagus nerve stimulation has recently received US Food and Drug Administration approval to improve upper limb recovery in individuals with chronic stroke. Although conventional vagus nerve stimulation systems have a long track record of solid performance, they have been minimally redesigned since their entry onto the market in 1997 and are ripe for improvement. To leverage this opportunity, we developed a miniaturized system tailored specifically for closed-loop vagus nerve stimulation therapy (CLV). The system is ≈50-fold smaller, simplifies implantation, and interacts with sensors for closed-loop triggering during personalized rehabilitation sessions. Here, we performed a randomized, sham-controlled trial to evaluate the safety, feasibility, and initial effectiveness of this system. METHODS: In the primary study, conducted from September 2021 to January 2024 in Dallas, TX, 19 participants with ischemic stroke that occurred at least 1 year prior and residual upper limb deficits were implanted. Participants entered the double-blinded phase, during which they were randomized to receive 18 sessions of individualized, progressive rehabilitation with active CLV or sham stimulation followed by an additional 18 sessions of rehabilitation with active CLV, regardless of prior group assignment. After completion of this primary study, a subset of participants entered an exploratory extension during which they received up to 100 additional sessions of self-paced CLV at home. RESULTS: Analysis of the primary outcome showed a nature and rate of adverse events similar to or below conventional vagus nerve stimulation devices. Heart rate and blood pressure were unaffected by CLV. Secondary functional outcomes demonstrated that, after CLV therapy in the randomized controlled trial phase, participants exhibited significant improvements in the upper extremity Fugl-Meyer score of 5.3±0.7 points over baseline (P<0.001). Additional therapy in the exploratory extension resulted in improvements of 10.9±1.3 points in upper extremity Fugl-Meyer score (P<0.001). CONCLUSIONS: These findings indicate that this miniaturized CLV system merits evaluation in a larger study. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04534556.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Hays SA, Adehunoluwa EA, Epperson JD, et al. Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. Stroke. 2025. PMID: 41054846. doi:10.1161/STROKEAHA.125.052937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。